Paolo Tarantino, MD

Articles

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

June 19th 2024

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

Dr Tarantino on Research in HR+ Breast Cancer

June 17th 2024

Paolo Tarantino, MD, and Yan Leyfman, MD, discuss ongoing investigations into the treatment of HR+ breast cancer presented at the 2024 ASCO Annual Meeting.

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

June 2nd 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer

December 4th 2023

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

Dr Tarantino on Understanding the Role of ADC Payloads in Breast Cancer

October 27th 2023

Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Tarantino on the Use of ADCs in HR+ Breast Cancer

August 22nd 2023

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

Dr Tarantino on Patient Awareness of the Platinum Shortage in Breast Cancer

August 18th 2023

Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.

Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer

August 9th 2023

Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.

Dr Tarantino on the Impact of Emerging ADCs in HR+ Breast Cancer

July 27th 2023

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer

July 17th 2023

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Emerging Concepts in mBC Treatment

March 2nd 2023

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.

Investigational ADCs for Treatment of TNBC

March 2nd 2023

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

The Role of ADCs in the Treatment of TNBC

February 22nd 2023

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)

February 22nd 2023

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

The Role of Capivasertib in ER+/HER- mBC

February 13th 2023

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

Use of Second-Generation Oral SERDs in ER+/HER2- mBC

February 7th 2023

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Standards of Care in the Frontline Treatment of ER+/HER2- mBC

January 30th 2023

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

January 30th 2023

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.